Loading
Extracellular Vesicles in Disease / Immune Cells in Cancer / Ferroptosis and Cancer Prognosis · Journal article
Cancer Biome and Targeted Therapy · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes mechanistic literature on how exosomal non-coding RNAs may regulate immune and metabolic pathways in triple-negative breast cancer. It identifies exosomal ncRNAs as potential liquid biopsy biomarkers and therapeutic targets but does not report original clinical or preclinical data, efficacy outcomes, or comparative evidence.
Journal article. Triple-negative breast cancer (TNBC), characterized by absence of ER, PR, and HER2 expression, with marked molecular heterogeneity, aggressive behavior, early metastatic dissemination, and poor prognosis..
Exosomes (30–150 nm diameter) are enriched in ncRNAs including miRNAs, lncRNAs, and circRNAs that regulate proliferation, apoptosis, invasion, EMT, angiogenesis, immune evasion, metabolic reprogramming, and therapy resistance in TNBC. Exosomal ncRNAs are proposed as emerging liquid biopsy biomarkers for diagnosis, prognostic stratification, and therapeutic monitoring. Potential therapeutic modalities discussed include antisense oligonucleotides (ASOs), antagomirs, and engineered exosome-based delivery platforms, though clinical validation remains incomplete.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies exosomal ncRNAs as potential biomarkers and therapeutic targets in TNBC but does not provide evidence sufficient to change clinical practice. Clinicians and researchers should view this as a framework for hypothesis generation and future translational research rather than as actionable clinical guidance.
This is a narrative review synthesizing mechanistic evidence on exosomal ncRNAs in TNBC without original data, primary endpoints, or clinical trials; it frames questions and therapeutic potential rather than testing them.
This review identifies exosomal ncRNAs as potential biomarkers and therapeutic targets in TNBC but does not provide evidence sufficient to change clinical practice. Clinicians and researchers should view this as a framework for hypothesis generation and future translational research rather than as actionable clinical guidance.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, limiting the applicability of endocrine and HER2-targeted therapies. Clinically, TNBC exhibits marked molecular heterogeneity, aggressive behavior, early metastatic dissemination, and poor prognosis relative to other breast cancer subtypes. Increasing evidence indicates that the tumor microenvironment (TME) plays a central role in TNBC progression and therapeutic resistance, with exosomes serving as key mediators of intercellular communication. Exosomes, extracellular vesicles measuring 30–150 nm in diameter, are enriched in non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), which regulate interconnected signaling pathways governing proliferation, apoptosis, invasion, epithelial-mesenchymal transition (EMT), angiogenesis, immune evasion, metabolic reprogramming, and therapy resistance. This review synthesizes current evidence on how exosomal ncRNAs orchestrate immune-metabolic networks that shape TNBC evolution and highlights their emerging clinical applications as liquid biopsy biomarkers for diagnosis, prognostic stratification, and therapeutic monitoring, as well as their potential as therapeutic targets via antisense oligonucleotides (ASOs), antagomirs, and engineered exosome-based delivery platforms. Finally, we discuss current translational challenges, including exosome heterogeneity, analytical standardization, and clinical validation, and outline future directions for integrating exosomal ncRNAs into precision management strategies for TNBC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.